Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects

References

• 5 Hive [Forum]. (2019, March). Retrieved from 5 Hive website: forums.5meodmt.org
   Google Scholar
• Agurell, S., B. Holmstedt, J. E. Lindgren, and R. E. Schultes. 1969. Alkaloids in certain species of Virola and other South American plants of ethnopharmacologic interest. Acta chemica Scandinavica 23 (3):903–16. doi:10.3891/acta.chem.scand.23-0903.
   PubMedGoogle Scholar
• Amrhein, V., F. Korner-Nievergelt, and T. Roth. 2017. The earth is flat (p > .05): Significance thresholds and the crisis of unreplicable research. Peer Journal 5:e3544. doi:10.7717/peerj.3544.
   PubMed Web of Science ®Google Scholar
• Araújo, A. M., F. Carvalho, M. de Lourdes Bastos, P. Guedes de Pinho, and M. Carvalho. 2015. The hallucinogenic world of tryptamines: An updated review. Archives of Toxicology 89 (8):1151–73. doi:10.1007/s00204-015-1513-x.
   PubMed Web of Science ®Google Scholar
• Arterberry, B. J., A. E. Smith, M. P. Martens, J. M. Cadigan, and J. G. Murphy. 2014. Protective behavioral strategies, social norms, and alcohol-related outcomes. Addiction Research & Theory 22 (4):279–85. doi:10.3109/16066359.2013.838226.
   PubMed Web of Science ®Google Scholar
• Bancopuma. (2017, May 21). Guidelines for 5-MeO-DMT use. Retrieved from 5 Hive website: https://forums.5meodmt.org/index.php?topic=50421.msg54151#msg54151
   Google Scholar
• Barrett, F. S., M. P. Bradstreet, J.-M. S. Leoutsakos, M. W. Johnson, and R. R. Griffiths. 2016. The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology (Oxford, England) 30 (12):1279–95. doi:10.1177/0269881116678781.
   PubMed Web of Science ®Google Scholar
• Barsuglia, J., A. K. Davis, R. Palmer, R. Lancelotta, A.-M. Windham-Herman, K. Peterson, … R. R. Griffiths. 2018. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Frontiers in Psychology 9. doi:10.3389/fpsyg.2018.02459.
   PubMed Web of Science ®Google Scholar
• Beyer, S. (2013, January 4). Traveling safely to drink ayahuasca. Retrieved from Ayahuasca.com website: http://www.ayahuasca.com/introductions/traveling-safely-to-drink-ayahuasca/
   Google Scholar
• Davis, A. K., and H. Rosenberg. 2016. Using the theory of planned behavior to predict implementation of harm reduction strategies by mdma/ecstasy users. Psychology of Addictive Behaviors 30:500–508. doi:10.1037/adb0000167.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., and H. Rosenberg. 2017. Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ecstasy users in the United States and the United Kingdom. Drug Science, Policy and Law 3:2050324517711069. doi:10.1177/2050324517711069.
   Google Scholar
• Davis, A. K., J. P. Barsuglia, R. Lancelotta, R. M. Grant, and E. Renn. 2018. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of Psychopharmacology (Oxford, England) 32 (7):779–92. doi:10.1177/0269881118769063.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., L. A. Osborn, J. Leith, H. Rosenberg, L. Ashrafioun, A. Hawley, … K. Baik. 2014. Development and evaluation of the Marijuana reduction strategies self-efficacy scale. Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors 28 (2):575–79. doi:10.1037/a0036665.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., S. So, R. Lancelotta, J. P. Barsuglia, and R. R. Griffiths. 2019. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse 45 (2):161–69. doi:10.1080/00952990.2018.1545024.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., A. K. Davis, F. Erowid, E. Erowid, R. R. Griffiths, and M. W. Johnson. 2019. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology 33:1088–1101. doi:10.1177/0269881119845793.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., A. K. Davis, F. Erowid, E. Erowid, R. R. Griffiths, and M. W. Johnson. 2020. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Frontiers in Psychiatry – Psychopharmacology 10:1–16. doi:10.3389/fpsyt.2019.00955.
   Web of Science ®Google Scholar
• Garcia-Romeu, A., R. R. Griffiths, and M. W. Johnson. 2015. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews 7 (3):157–64. doi:10.2174/1874473708666150107121331.
   Google Scholar
• Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, … M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology (Oxford, England) 30 (12):1181–97. doi:10.1177/0269881116675513.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, W. A. Richards, B. D. Richards, U. McCann, and R. Jesse. 2011. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 218 (4):649–65. doi:10.1007/s00213-011-2358-5.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, U. McCann, and R. Jesse. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187 (3):268–283; discussion 284–292. doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Hendricks, P. S., C. B. Thorne, C. B. Clark, D. W. Coombs, and M. W. Johnson. 2015. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology (Oxford, England) 29 (3):280–88. doi:10.1177/0269881114565653.
   PubMed Web of Science ®Google Scholar
• IBM Corp. 2016. IBM SPSS statistics for windows (Version 24.0) [Windows]. Armonk, NY: IBM Corp.
   Google Scholar
• Johnson, M. W., and R. R. Griffiths. 2017. Potential therapeutic effects of psilocybin. Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics 14 (3):734–40. doi:10.1007/s13311-017-0542-y.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., W. A. Richards, and R. R. Griffiths. 2008. Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology (Oxford, England) 22 (6):603–20. doi:10.1177/0269881108093587.
   PubMed Web of Science ®Google Scholar
• Leonard, J. B., B. Anderson, and W. Klein-Schwartz. 2018. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. Journal of Psychopharmacology (Oxford, England) 32 (12):1286–94. doi:10.1177/0269881118793086.
   PubMed Web of Science ®Google Scholar
• Liana, L. (2017). Preparing for ayahuasca ceremony—the uncensored guide. Retrieved from EntheoNation website: https://entheonation.com/blog/ayahuasca-ceremony-preparation-dieta/
   Google Scholar
• Maclean, K. A., J.-M. S. Leoutsakos, M. W. Johnson, and R. R. Griffiths. 2012. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion 51 (4):721–37. doi:10.1111/j.1468-5906.2012.01685.x.
   PubMed Web of Science ®Google Scholar
• Marlatt, G. A., M. E. Larimer, and K. Witkiewitz. 2012. Harm reduction, second edition: Pragmatic strategies for managing high-risk behaviors. New York, NY: Guilford Press.
   Google Scholar
• Martens, M. P., A. G. Ferrier, M. J. Sheehy, K. Corbett, D. A. Anderson, and A. Simmons. 2005. Development of the protective behavioral strategies survey. Journal of Studies on Alcohol 66 (5):698–705. doi:10.15288/jsa.2005.66.698.
   PubMed Web of Science ®Google Scholar
• Mckenna, D. J., G. H. N. Towers, and F. S. Abbott. 1984. Monoamine oxidase inhibitors in South American hallucinogenic plants part 2: Constituents of orally-active Myristicaceous hallucinogens. Journal of Ethnopharmacology 12 (2):179–211. doi:10.1016/0378-8741(84)90048-5.
   PubMed Web of Science ®Google Scholar
• Pedersen, E.R., W. Huang, R.D. Dvorak, M.A. Prince, and J.F. Hummer. 2017. The protective behavioral strategies for marijuana scale: Further examination using item response theory. Psychol. Addict. Behav. 31:548–559.
   Web of Science ®Google Scholar
• Perneger, T. V. 1998. What’s wrong with Bonferroni adjustments. BMJ 316 (7139):1236–38. doi:10.1136/bmj.316.7139.1236.
   PubMed Web of Science ®Google Scholar
• Psychedelics Today. (2017, November 21). Rafael Lancelotta—Exploring 5-MeO-DMT. Retrieved from Psychedelics Today website: https://psychedelicstoday.com/2017/11/21/rafael-lancelotta-5-meo-dmt/
   Google Scholar
• Rubin, M. 2017. Do p values lose their meaning in exploratory analyses? It depends how you define the familywise error rate. Review of General Psychology 21 (3):269–75. doi:10.1037/gpr0000123.
   Web of Science ®Google Scholar
• Schultes, R. E. 1984. Fifteen years of study of psychoactive snuffs of South America: 1967–1982- a review. Journal of Ethnopharmacology 11 (1):17–32. doi:10.1016/0378-8741(84)90093-X.
   PubMed Web of Science ®Google Scholar
• Sexton, J. D., M. S. Crawford, N. W. Sweat, A. Varley, E. E. Green, and P. S. Hendricks. 2019. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. Journal of Psychopharmacology (Oxford, England) 269881119827796. doi:10.1177/0269881119827796.
   Web of Science ®Google Scholar
• Shen, H.-W., X.-L. Jiang, J. C. Winter, and A.-M. Yu. 2010. Psychedelic 5-Methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Current Drug Metabolism 11 (8):659–66. doi:10.2174/138920010794233495.
   PubMed Web of Science ®Google Scholar
• Shulgin, A., and A. Shulgin. 1997. TiHKAL: The continuation (First). Berkeley, California:Transform Press.
   Google Scholar
• Sklerov, J., B. Levine, K. A. Moore, T. King, and D. Fowler. 2005. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. Journal of Analytical Toxicology 29 (8):838–41. doi:10.1093/jat/29.8.838.
   PubMed Web of Science ®Google Scholar
• The Conclave. (2018, May 28). INTEGRATION GUIDELINES from The Conclave. Retrieved from 5 Hive website: https://forums.5meodmt.org/index.php?topic=50731.0
   Google Scholar
• Thomas, K., B. Malcolm, and D. Lastra. 2017. Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disorders. Journal of Psychoactive Drugs 49 (5):446–55. doi:10.1080/02791072.2017.1320734.
   PubMed Web of Science ®Google Scholar
• Toad & 5-MeO Forum & Support [Social Media]. (2019, March). Retrieved from Facebook website: https://www.facebook.com/groups/813691418706935/
   Google Scholar
• Torres, C. M., and D. B. Repke. 2006. Anadenanthera: Visionary plant of ancient South America. New York: Haworth Herbal Press.
   Google Scholar
• Trout, K. (2015, February 10). Erowid online books: “Ayahuasca: Alkaloids, plants, and analogs” by keeper of the trout. Retrieved from https://erowid.org/library/books_online/ayahuasca_apa/aya_sec3_part2_anadenanthera_analysis.shtml
   Google Scholar
• Uthaug, M. V., R. Lancelotta, A. Szabo, A. K. Davis, J. Riba, and J G. Ramaekers (2019). Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: Effects on salivary IL-6, cortisol levels, affect, and non-judgement. Psychopharmacology. E-pub ahead of print. doi:10.1007/s00213-019-05414-w
   Google Scholar
• VICELAND. (2017). Hamilton Morris learns about the toad ceremonies of the Yaqui Tribe. Retrieved from https://www.youtube.com/watch?v=M5U9D7Y5er4
   Google Scholar
• Weil, A. T., and W. Davis. 1994. Bufo alvarius: A potent hallucinogen of animal origin. Journal of Ethnopharmacology 41 (1–2):1–8. doi:10.1016/0378-8741(94)90051-5.
   PubMed Web of Science ®Google Scholar
• Winstock, A. R., S. Kaar, and R. Borschmann. 2014. Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample. Journal of Psychopharmacology (Oxford, England) 28 (1):49–54. doi:10.1177/0269881113513852.
   PubMed Web of Science ®Google Scholar